Abstract
The lower gastrointestinal tract is a major mucosal site of HIV entry and initial infection. Thus, the induction of strong cellular immune responses at this mucosal site will be an important feature of an effective HIV vaccine. We have used a novel prime-boost vaccination approach to induce immune responses at mucosal sites. Orally delivered recombinant Clostridium perfringens expressing HIV-1 gag (Cp-Gag) was evaluated for induction of HIV-1 Gag specific T cell responses in a prime-boost model with intranasal inoculation of HIV-1 virus like particles (VLP). HIV-1 specific cellular immune responses in both the effector (Lamina propria) and inductive sites (Peyers patches) of the gastrointestinal (GI) tract were significantly higher in mice immunized using Cp-Gag and VLPs in a prime-boost approach compared to mice immunized with either Cp-Gag or VLPs alone. Such cellular immune response was found to be mediated by both CD8+ and CD4+ T cells. Such a strong mucosal immune response could be very useful in developing a mucosal vaccine against HIV-1.
Keywords: HIV, mucosal vaccine, Clostridium perfringens, virus like particles, mucosal immunity, gastrointestinal tract, immune responses, Adjuvants, Immunization, Sample Collection
Current HIV Research
Title: Induction of Strong Anti-HIV Cellular Immunity by a Combination of Clostridium Perfringens Expressing HIV Gag and Virus Like Particles
Volume: 9 Issue: 8
Author(s): Poonam Pegu, Ruth Helmus, Phalguni Gupta, Patrick Tarwater, Lori Caruso, Chengli Shen, Ted Ross and Yue Chen
Affiliation:
Keywords: HIV, mucosal vaccine, Clostridium perfringens, virus like particles, mucosal immunity, gastrointestinal tract, immune responses, Adjuvants, Immunization, Sample Collection
Abstract: The lower gastrointestinal tract is a major mucosal site of HIV entry and initial infection. Thus, the induction of strong cellular immune responses at this mucosal site will be an important feature of an effective HIV vaccine. We have used a novel prime-boost vaccination approach to induce immune responses at mucosal sites. Orally delivered recombinant Clostridium perfringens expressing HIV-1 gag (Cp-Gag) was evaluated for induction of HIV-1 Gag specific T cell responses in a prime-boost model with intranasal inoculation of HIV-1 virus like particles (VLP). HIV-1 specific cellular immune responses in both the effector (Lamina propria) and inductive sites (Peyers patches) of the gastrointestinal (GI) tract were significantly higher in mice immunized using Cp-Gag and VLPs in a prime-boost approach compared to mice immunized with either Cp-Gag or VLPs alone. Such cellular immune response was found to be mediated by both CD8+ and CD4+ T cells. Such a strong mucosal immune response could be very useful in developing a mucosal vaccine against HIV-1.
Export Options
About this article
Cite this article as:
Pegu Poonam, Helmus Ruth, Gupta Phalguni, Tarwater Patrick, Caruso Lori, Shen Chengli, Ross Ted and Chen Yue, Induction of Strong Anti-HIV Cellular Immunity by a Combination of Clostridium Perfringens Expressing HIV Gag and Virus Like Particles, Current HIV Research 2011; 9 (8) . https://dx.doi.org/10.2174/157016211798998808
DOI https://dx.doi.org/10.2174/157016211798998808 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV Vaccine Development.
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in People Living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
EMCA and DEEM as Michael Reagents Used in Organic Synthesis
Current Organic Chemistry Chemistry and Applications of 4-Hydroxyquinolin-2-one and Quinoline-2,4-dionebased Compounds
Current Organic Chemistry Clinical Studies with Paclitaxel - Eluting Stent Systems
Current Pharmaceutical Design Graphical Abstracts:
Letters in Drug Design & Discovery The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Reversal in Cognition Impairments, Cholinergic Dysfunction, and Cerebral Oxidative Stress Through the Modulation of Ryanodine Receptors (RyRs) and Cysteinyl Leukotriene-1 (CysLT1) Receptors
Current Neurovascular Research Patent Selections
Recent Patents on Drug Delivery & Formulation Molecular Pathogenesis of Chronic Lymphocytic Leukemia
Current Molecular Medicine Circulating MicroRNAs: Diagnostic Value as Biomarkers in the Detection of Non-alcoholic Fatty Liver Diseases and Hepatocellular Carcinoma
MicroRNA Engineered Bacteria: General Overview as Therapeutic Agent and a Novel Drug Delivery System
Current Pharmaceutical Biotechnology Atherosclerosis is an Inflammatory Disorder After All
Current Topics in Medicinal Chemistry The Role of the Cell Surface LRP and Soluble LRP in Blood-Brain Barrier Aβ Clearance in Alzheimers Disease
Current Pharmaceutical Design Hepatic Disposition of Electrophilic Acyl Glucuronide Conjugates
Current Drug Metabolism Role of Exosomes in Breast Cancer Management: Evidence-Based Review
Current Cancer Drug Targets Immunologic Impact of Nutrient Depletion in Chronic Obstructive Pulmonary Disease
Current Drug Targets Community-Acquired Pneumonia and Outcome: The Importance of Genetics
Current Respiratory Medicine Reviews Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design Flunarizine Dihydrochloride Nanoemulsion for Migraine Nasal Drug Delivery: Fabrication, Characterization and In Vitro Study
Drug Delivery Letters Molecular Therapy Intervention Prospects in Prostate Cancer
Current Pharmaceutical Design Natural Products and Transforming Growth Factor-beta (TGF-β) Signaling in Cancer Development and Progression
Current Cancer Drug Targets